Medications

US panel backs inhaler drug for lung disease

A panel of U.S. respiratory experts voted Wednesday in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravance for treating chronic lung disease.

Medications

UK alleges GSK paid off competitors to delay drugs

Britain's competition watchdog accused GlaxoSmithKline on Friday of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat.

Medications

China crystal meth makers used GSK cold medicine: report

Some crystal methamphetamine seized in a huge drug bust in China used the popular cold medicine Contac, manufactured by beleaguered British drugmaker GlaxoSmithKline (GSK), state media reported Tuesday.

Other

GlaxoSmithKline says Q3 net profits drop 18.5%

British drugmaker GlaxoSmithKline said Wednesday that third-quarter net profits fell 18.5 percent from a year earlier to £1.12 billion ($1.80 billion, 1.39 billion euros), hit by weak conditions in Europe.

Medications

GlaxoSmithKline opts to hold on to HIV business

British-based drugmaker GlaxoSmithKline opted Wednesday to keep its stake in its stand-alone HIV business as it set out its strategy following a big deal with Switzerland's Novartis.

Other

GlaxoSmithKline profits up on lower tax

British drugmaker GlaxoSmithKline on Wednesday said its second quarter net profit rose 13.3 percent from a year earlier to £1.25 billion ($1.94 billion, 1.59 billion euros).

Medications

Elan enters $1B royalty deal with Theravance

Irish drugmaker Elan Corp. PLC plans to pay $1 billion for the right to future royalties from four respiratory treatments being developed by Theravance Inc. and GlaxoSmithKline.

Medications

Flu vaccine linked to narcolepsy in under 30s: study

A vaccine used in Sweden in the 2009-2010 "swine flu" pandemic is linked to a higher risk of the sleeping disorder narcolepsy among under 30s, and not just children and teens as previously thought, a Swedish study showed ...

Medications

FDA weighs lifting safety restrictions on Avandia (Update 2)

A former blockbuster diabetes pill that was subjected to major safety restrictions in 2010 may be less risky than once thought, according to the latest analysis of the much-debated GlaxoSmithKline drug Avandia.

page 7 from 18